Aemetis (NASDAQ:AMTX) Stock Price Crosses Below Two Hundred Day Moving Average of $4.22

Aemetis, Inc. (NASDAQ:AMTX)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.22 and traded as low as $3.41. Aemetis shares last traded at $3.45, with a volume of 569,248 shares changing hands.

Analyst Ratings Changes

Several research analysts have recently commented on AMTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price target on shares of Aemetis in a report on Friday, May 10th. Stifel Nicolaus cut their price objective on Aemetis from $8.00 to $6.50 and set a “buy” rating for the company in a report on Wednesday, February 21st. Truist Financial restated a “hold” rating and issued a $4.00 price target (up previously from $3.50) on shares of Aemetis in a research report on Monday, May 13th. Finally, StockNews.com upgraded Aemetis to a “sell” rating in a research report on Monday, May 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.40.

Aemetis Price Performance

The business has a 50-day simple moving average of $4.33 and a two-hundred day simple moving average of $4.21.

Aemetis (NASDAQ:AMTX) last posted its earnings results on Thursday, March 7th. The specialty chemicals company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01. The firm had revenue of $70.76 million during the quarter, compared to analyst estimates of $80.08 million. During the same quarter in the previous year, the business posted ($0.63) earnings per share. Sell-side analysts expect that Aemetis, Inc. will post -1.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director John R. Block sold 51,580 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $3.49, for a total value of $180,014.20. Following the completion of the transaction, the director now directly owns 14,001 shares in the company, valued at $48,863.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 14.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aemetis

A number of hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Aemetis in the first quarter worth $60,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Aemetis during the first quarter worth approximately $84,000. Barclays PLC bought a new stake in shares of Aemetis during the third quarter valued at approximately $150,000. Citigroup Inc. grew its stake in shares of Aemetis by 10,391.3% during the third quarter. Citigroup Inc. now owns 75,013 shares of the specialty chemicals company’s stock valued at $311,000 after purchasing an additional 74,298 shares during the last quarter. Finally, Stifel Financial Corp increased its holdings in shares of Aemetis by 58.0% in the third quarter. Stifel Financial Corp now owns 691,445 shares of the specialty chemicals company’s stock valued at $2,870,000 after purchasing an additional 253,745 shares in the last quarter. Institutional investors and hedge funds own 27.02% of the company’s stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.